Alterity Therapeutics Completes Last Patient Visit in Open-Label Trial
Ticker: PRNAF · Form: 6-K · Filed: Mar 27, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Mar 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: clinical-trial, biotech, filing-update
TL;DR
Alterity Therapeutics just finished its last patient visit for a trial. Big news coming soon.
AI Summary
Alterity Therapeutics Ltd. announced on March 27, 2025, that it has completed the last patient visit for its open-label trial. This marks a significant step in the company's development stage, with the results of this trial expected to inform future clinical strategies.
Why It Matters
Completion of patient visits is a key milestone in clinical trials, bringing the company closer to data analysis and potential future drug development decisions.
Risk Assessment
Risk Level: medium — Clinical trial progress is a critical but inherently uncertain factor in biotechnology companies, carrying inherent risks.
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant and subject of the filing
- March 2025 (date) — Reporting period for the Form 6-K
- 350 Collins Street, Melbourne, Victoria 3000 Australia (address) — Principal Executive Office of Alterity Therapeutics Ltd.
- PRANA BIOTECHNOLOGY LTD (company) — Former company name of Alterity Therapeutics Ltd.
FAQ
What is the purpose of the open-label trial mentioned in the filing?
The filing does not specify the purpose of the open-label trial, only that the last patient visit has been completed.
When is Alterity Therapeutics expected to release results from this trial?
The filing does not provide a timeline for the release of trial results.
Which specific registration statements is this Form 6-K being incorporated by reference into?
This Form 6-K is incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
What is Alterity Therapeutics' former company name?
Alterity Therapeutics' former company name was PRANA BIOTECHNOLOGY LTD.
What is the principal executive office address of Alterity Therapeutics?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 27, 2025 regarding ALTERITY THERAPEUTICS LTD (PRNAF).